Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
Details : Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Product Name : Exelon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2022
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
Details : Exelon Patch (rivastigmine transdermal system) is a class of medications called cholinesterase inhibitors, which is used to manage and treat neurodegenerative disease, specifically dementia, in patients with Alzheimer and Parkinson disease.
Product Name : Exelon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2022
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia
Details : Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Product Name : Exelon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estradiol,Progesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : TherapeuticsMD
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
Details : BIJUVA is a once-daily combination of estradiol and progesterone in a single oral capsule that will be available in two strengths in Canada indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an in...
Product Name : Bijuva
Product Type : Hormone
Upfront Cash : Inapplicable
September 21, 2020
Lead Product(s) : Estradiol,Progesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : TherapeuticsMD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
Details : In Canada, IMVEXXY is approved for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA).
Product Name : Imvexxy
Product Type : Hormone
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Neratinib,Capecitabine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The SNDS is supported by the results of the Phase IIINALA trial, a randomized controlled trial of neratinib plus capecitabine versus Tykerb® (lapatinib) plus capecitabine in HER2-positive metastatic breast cancer patients previously treated with = 2 HER...
Product Name : Nerlynx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : Neratinib,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable